These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Cottrell DA; Marshall BJ; Falko JM Curr Opin Cardiol; 2003 Jul; 18(4):301-8. PubMed ID: 12858129 [TBL] [Abstract][Full Text] [Related]
6. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans. Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454 [TBL] [Abstract][Full Text] [Related]
7. [Diabetic dyslipidaemia and the atherosclerosis]. Márk L; Dani G Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274 [TBL] [Abstract][Full Text] [Related]
8. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Temelkova-Kurktschiev T; Hanefeld M Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):75-9. PubMed ID: 15031770 [TBL] [Abstract][Full Text] [Related]
9. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. de Vries R; Borggreve SE; Dullaart RP Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331 [TBL] [Abstract][Full Text] [Related]
10. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Chapman MJ; Guérin M; Bruckert E Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339 [TBL] [Abstract][Full Text] [Related]
11. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Brunzell JD; Ayyobi AF Am J Med; 2003 Dec; 115 Suppl 8A():24S-28S. PubMed ID: 14678862 [TBL] [Abstract][Full Text] [Related]
12. HDL cholesterol and protective factors in atherosclerosis. Assmann G; Gotto AM Circulation; 2004 Jun; 109(23 Suppl 1):III8-14. PubMed ID: 15198960 [TBL] [Abstract][Full Text] [Related]
13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
14. Dyslipidemia of the metabolic syndrome. Ruotolo G; Howard BV Curr Cardiol Rep; 2002 Nov; 4(6):494-500. PubMed ID: 12379172 [TBL] [Abstract][Full Text] [Related]
15. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Linsel-Nitschke P; Tall AR Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977 [TBL] [Abstract][Full Text] [Related]